Abstract
Depression and anxiety are the most common and frequently disabling psychiatric conditions that accompany Parkinson’s disease (PD). Although James Parkinson, in his original report of six patients, wrote that the “senses and intellect being uninjured” (1), he still used descriptions like “melancholy” and “unhappy sufferer.” In early 1920s, some authors argued that “abnormal psychic functioning” was a part of the disease process and that “the mental set was always depressive” (2). Nowadays, it is widely accepted that, despite discrepancies in patient selection, inconsistent definitions of depression, and different methods of assessment, a considerable risk of depression appears to accompany PD. Depressive symptoms in parkinsonian patients have been classified as “organic mood syndrome” in the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM-IIIR) and as “mood disorder due to a general medical condition” in DSM-IV. Although the exact etiology of depression in PD is unclear, available evidence suggests that biochemical changes, psychosocial factors, and situational stressors may all contribute to its development (3). Finally, although major depression (MD) may occur in PD, studies indicate that the majority of depressed parkinsonians have less severe forms such as minor depression, dysthymic disorder, and subsyndromal forms (4–6).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Parkinson, J. (1817) An Essay on the Shaking Palsy Sherwood, Neely and Jones, London.
Jackson, J.A., Free, G.B.M., and Pike, H.V. (1923) The psychic manifestations in paralysis agitans, Arch. Neurol. 10, 680–684.
Zesiewicz, T.A., Gold, M., Chari, G., and Hauser, R.A. (1999) Current issues in depression in Parkinson’s disease. Am. J. Geriatr. Psychiatry 7, 110–118.
Tandberg, E., Larsen, J.P., Aarsland, D., and Cummings, J.L. (1996) The occurrence of depression in Parkinson’s disease: the community based study. Arch. Neurol. 53, 175–179.
Liu, C.-Y., Wang, S.-J., Fuh, J.-L., Lin, C.-H., Yang Y.-Y., and Liu, H.-C. (1997) The correlation of depression with functional activity in Parkinson’s disease. J. Neurol. 244, 493–498.
Starkstein, S.E., Petricca, G., Shemerinski, E., et al. (1998) Depression in classic versus akinetic-rigid Parkinson’s disease. Mov. Disord. 13, 29–33.
Klaassen, T., Verhey, F.R., Sneijders, G.H., Rozendaal, N., de Vet, H.C., and van Praag, H.M. (1995) Treatment of depression in Parkinson’s disease: a meta-analysis. J. Neuropsychiatry Clin. Neurosci. 7, 281–286.
Gotham, A.M., Brown, R.G., and Marsden, C.D. (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49, 381–389.
Cummings, J.L. (1992) Depression in Parkinson’s disease: a review. Am. J. Psychiatry 149, 443–454.
Kostić, V.S., Filipović, S.R., Lečić, D., Momcilovic, D., Sokic, D., and Sternić, N. (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 57, 1265–1267.
Giladi, N., Treves, T.A., Paleacu, D., et al. (2000) Risk factors for dementia, depression and psychosis in longstanding Parkinson’s disease. J. Neural. Transm. 107, 59–71.
Caap-Ahlgren, M. and Dehlin, O. (2001) Insomnia and depressive symptoms in patients with Parkinson’s disease— relationship to health-related quality of life. An interview study of patients living at home. Arch. Gerontol. Geriatr. 32, 23–33.
Doonief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y., and Mayeux, R. (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch. Neurol. 49, 305–307.
Hantz, P., Caradoc-Davies, G., Caradoc-Davies, T., Weatherall, M., and Dixon, G. (1994) Depression in Parkinson’s disease. Am. J. Psychiatry 151, 1010–1014.
Aarsland, D., Larsen, J.P., Lim, N.G., et al. (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496.
Schrag, A., Jahanshahi, M., and Quinn, N.P. (2001) What contributes to depression in Parkinson’s disease? Psychol. Med. 31, 65–73.
Brown, R. and Jahanshahi, M. (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv. Neurol. 65, 61–84.
Henderson, R., Kurlan, R., and Kersun, J.M. (1992) Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 4, 257–264.
Menza, M.A., Robertson-Hoffman, D.E., and Bonapace, A.S. (1993) Parkinson’s disease and anxiety: comorbidity with depression. Biol. Psychiatry 34, 465–470.
Walsh, K. and Bennett, G. (2001) Parkinson’s disease and anxiety. Postgrad. Med. J. 77, 89–93.
Shiba, M., Bower, J.H., Maraganore, D.M., et al. (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov. Disord. 15, 669–677..
Rabinstein, A.A. and Shulman, L.M. (2001) Management of behavioral and psychiatric problems in Parkinson’s disease. Parkinsonism Rel. Disord. 7, 41–50.
American Psychiatric Association. (1994) Diagnostic and statistical manual or mental disorders (4tn ed.). wasnington, DC, APA.
Melamed, E. (1997) Neurobehavioral abnormalities in Parkinson’s disease, in Movement Disorders: Neurologic Principles and Practice (Watts, R.L. and Koller, W.C., eds.), McGraw-Hill, New York, pp. 257–262.
Shulman, L.M., Leifert, R., Singer, C., and Weiner, W.J. (1997) The diagnostic accuracy ot neurologists tor anxiety, depression, fatigue, and sleep disorders in Parkinson’s disease [abstract]. Mov. Disord. 12, 127.
Sutor, B., Rummans, T.A., Jowsey, S.G., et al. (1998) Major depression in medically ill patients. Mayo Clin. Proc. 73, 329–337.
Starkstein, S.E., Preziosi, T.J., Bolduc, P.L., and Robinson, R.G. (1990) Depression in Parkinson’s disease. J. Nerv. Ment. Dis. 178, 27–31.
Vallderiolla, F., Nobbe, F.A., and Tolosa, E. (1997) Treatment of behavioral disturbances in Parkinson’s disease. J. Neural. Transm. 51, 175–204.
Starkstein, S.E., Preziosi, T.J., Forrester, A.W., and Robinson, R.G. (1990) Specificity of affective and autonomic symptoms of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 53, 869–873.
Marinković, Z., Kostić, V.S., Sternié, N., and Marinković, S. (1990) Pain in Parkinson’s disease. Serb. Arch. 118, 459–462.
Menza, M.A. and Rosen, R.C. (1995) Sleep in Parkinson’s disease: the role of depression and anxiety. Psychosomatics 36, 262–266.
Kostid, V.S., Šušid, V., Przedborski, S., and Sternié, N. (1991) Sleep EEG in depressed and nondepressed patients with Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 3, 99–103.
Friedman, J. and Friedman, H. (1993) Fatigue in Parkinson’s disease. Neurology 43, 2016–2018.
Hoogendijk, W.J.G., Sommer, I.E.C., Tissingh, G., Deeg, D.J.H., and Wolters, E.C. (1998) Depression in Parkinson’s disease. Psychosomatics 39, 416–421.
Cantello, R., Gilli, M., Riccio, A., and Bergamasco, B. (1986) Mood changes associated with end-of-dose-deterioration in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 49, 1182–1190.
Levin, B.E., Llabre, M.M., and Weiner, W.J. (1988) Parkinson’s disease and depression: psychometric properties or the Beck Depression Inventory. J. Neurol. Neurosurg. Psychiatry 51, 1401–1404.
Leentjens, A.F.G., Verhey, F.R.J., Luijckx, G.-J., and Troost, J. (2000) The validity of the Beck Depression inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov. Disord. 15, 1221–1224.
Leentjens, A.F.G., Verhey, F.R.J., Lousberg, R., Spitsbergen, H., and Wilmink, F.W. (2000) The validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as screening and diagnostic instrument for depression in patients with Parkinson’s disease. Int. J. Geriatr. Psychiatry 15, 644–649.
Cole, S.A., Woodard, J.L., Juncos, J.L., Kogos, J.L., Youngstrom, E.A., and Watts, R.L. (1996) Depression and disability in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 8, 20–25.
Starkstein, S.E., Mayberg, H.S., Leiguarda, R., Preziosi, T.J., and Robinson, R.G. (1992) A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 55, 377–382.
Tom, T. and Cummings, J.L. (1998) Depression in Parkinson’s disease: pharmacological characteristics and treatment. Drugs Aging 12, 55–74.
Marder, K., Tang, M.X., Cote, L., Stern, Y., and Mayeux, R. (1995) The frequency and associated risx factors for dementia in patients with Parkinson’s disease. Arch. Neurol. 52, 695–701.
Karlsen, K.H., Larsen, J.P., Tandberg, E., and Maeland, J.G. (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. Neurol. Neurosurg. Psychiatry 66, 431–435.
Kuopio, A.-M., Martilla, R.J., Helenius, H., Toivonen, M., and Rinne, U.K. (2000) The quality of lite in Parkinsons disease. Mov. Disord. 15, 216–223.
Lasser, R., Siegel, E., Dukoff, R., and Sunderland, T. (1998) Diagnosis and treatment or geriatric depression. CNS Drugs 9, 17–30.
Richard, I.H. and Kurlan, R. (1997) A survey of antidepressant drug use in Parkinson’s disease. Neurology 49, 1168–1170.
Maricle, R.A., Nutt, J.G., Valentine, R.J., and Carter, J.H. (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 45, 1757–1760.
Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E., and Hoehn, M.M. (1969) Treatment of parkinsonism with levodopa. Arch. Neurol. 21, 343–354.
Damasio, A.R., Antunes, J.L., and Macedo, C. (1970) L-dopa, parkinsonism, and depression. Lancet 2, 611–612.
Marsh, G.G. and Markham, C.H. (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J. Neurol. Neurosurg. Psychiatry 36, 925–935.
Growdon, J.H., Kieburtz, K., McDermott, M.P., Panisset, M., and Friedman, J.H. (1998) Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Parkinson Study Group. Neurology 50, 1327–1331.
Choi, C., Sohn, Y.H., Lee, J.H., and Kim, J.-S. (2000) The effect of long-term levodopa therapy on depression in de novo patients with Parkinson’s disease. J. Neurol. Sci. 172, 12–16.
Vazquez, A., Jimenez-Jimenez, FJ., Garcia-Ruiz, P., and Garcia-Urra, D. (1993) “Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapy. Acta Neurol. Scand. 87, 14–18.
Theohar, C., Fischer-Cornelssen, K., Akesson, H.O., Ansari, H., Gerlach, J., and Harper, P. (1981) Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr. Ther. Res. 30, 830–842.
Inoue, T., Tsuchiya, K., Miura, J., et al. (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressantresistant depression. Biol. Psychiatry 40, 151–153.
MacGrath, P.J., Quitkin, F.M., and Klein, D.F. (1995) Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J. Clin. Psychopharmacol. 15, 289–291.
Jouvent, R., Abensour, P., Bonnet, A.M., Widlocher, D., Agid, Y., and Lhermitte, F. (1983) Antiparkinsonian and antidepressant effects of high doses bromocriptine. J. Affect. Disord. 5, 141–145.
Factor, S.A., Molho, E.S., Podskalny, G.D., and Brown, D. (1995) Parkinson’s disease: drug-induced psychiatric states. Adv. Neurol. 65, 115–138.
Przedborski, S., Liard, A., and Hildebrand, J. (1992) Induction of mania by apomorphine in a depressed parkinsonian patient. Mov. Disord. 7, 285–287.
Sporn, J., Gnaemi, S.N., Sambur, M.R., et al. (2000) Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12, 137–140.
Corrigan, M.H., Denahan, A.Q., Wright, C.E., Ragual, R.J., and Evans, D.L. (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11, 58–65.
Flaherty, J.A. and Bellur, S.N. (1981) Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J. Clin. Psychiatry 42, 344–345.
Dietrich, D.E., Bode, L., Spannhuth, C.W., et al. (2000) Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2, 65–70.
Moreau, J.L., Borgulya, J., Jenck, F., and Martin, J.R. (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav. Pharmacol. 5, 344–350.
Fava, M., Rosenbaum, J.F., Kolsky, A.R., et al. (1999) Open study of the catechol-O-methyltransferase inhibitor tolacapone in major depressive disorder. J. Clin. Psychopharmacol. 19, 329–335.
Bresa, G.M. (1994) S-adenosyl-L-methionine as antidepressant: a meta analysis of clinical studies. Acta Neurol. Scand. 154(Suppl), 7–14.
Di Rocco, A., Rogers, J.D., Brown, R., Werner, P., and Bottiglieri, T. (2000) S-adenosyl-methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov. Disord. 15, 1225–1229.
Bejjani, B.-P., Damier, P., Arnulf, I., et al. (1999) Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med. 340, 1476–1480.
Bezerra, M.L.S., Martinez, J.-V.L., and Nasser, J.A. (1999) Transient acute depression induced by high-frequency deep-brain stimulation [correspondence]. N. Engl. J. Med. 340, 1003–1004.
Ghika, J., Ghika-Schmid, F., Fankhauser, H., et al. (1999) Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J. Neurosurg. 91, 313–321.
Straits-Toster, K., Fields, JA., Wilkinson, S.B., et al. (2000) Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn. 42, 399–416.
Bakish, D., Habib, R., and Hooper, C.L. (1998) Mixed anxiety and depression: diagnosis and treatment options. CNS Drugs 9, 271–180.
Denmark, J.C., David, J.D.P., and McComb, S.G. (1961) Imipramine hydrochloride (Tofranil) in parkinsonism: a preliminary report. Br. J. Clin. Pract. 15, 523–524.
Strang, R.R. (1965) Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 2, 33–34.
Laitinen, L. (1969) Desipramine in treatment of parkinson’s disease: a placebo-controlled study. Acta Neurol. Scand. 45, 109–113.
Andersen, J., Aabro, E., Gulmann, N., Hjelmsted, A., and Pedersen, H.E. (1980) Antidepressive treatment in Parkinson’s disease. Acta Neurol. Scand. 62, 210–219.
Indaco, A. and Carrieri, P.D. (1988) Amitryptiline in the treatment of headache in patients with Parkinson’s disease. Neurology 38, 1720–1722.
Cummings, J.L. and Masterman, D.A. (1999) Depression in patients with Parkinson’s disease. Int. J. Geriatr. Psychiatry 14, 711–718.
Cunningham, L.A. (1994) Depression in medically ill: choosing an antidepressant. J. Clin. Psychiatry 55(Suppl. A), 98–100.
Meara, R.J., Bhowmick, B.K., and Hobson, J.P. (1996) An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson’s disease. J. Serotonin Res. 4, 243–249.
Hauser, R.A. and Zesiewicz, T.A. (1997) Sertraline for the treatment of depression in Parkinson’s disease. Mov. Disord. 12, 756–757.
Wittgens, W., Donath, O., and Trenckmann, U. (1997) Treatment of depressive syndromes in Parkinson’s disease with paroxetine [abstract]. Mov. Disord. 12, 128.
Ceravolo, R., Nuti, A., Piccinni, A., et al. (2000) Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 55, 1216–1218.
McCance-Katz, E.F., Marek, K.L., and Price, L.H. (1992) Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 42, 1813–1814.
Mayeux, R., Stern, Y., Sano, M., Williams, J.B., and Cote, L.J. (1988) The relationship of serotonin to depression in Parkinson’s disease. Mov. Disord. 3, 237–244.
Kostić, V.S., Djuričić, B.M., ternié, N., Bumbaširević, L.J., Nikolié, M., and Mršulja, B.B. (1987) Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J. Neurol. 234, 94–96.
Kostié, V.S., Lečić, D., Doder, M., Marinković, J., and Filipović, S. (1996) Prolactine and cortisol responses to fenfluramine in Parkinson’s disease. Biol. Psychiatry 40, 769–775.
Chouinard, G. and Sultan, S. (1992) A case of Parkinson’s disease exacerbated by fluoxetine. Hum. Psychopharmacol. 7, 63–66.
Jansen-Steur, E.N.H. (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43, 211–213.
Jimenez-Jimenez, F.J., Tejeiro, J., Martinez-Junquera, G., et al. (1994) Parkinsonism exacerbated by paroxetine [letter]. Neurology 44, 2406.
Linazasoro, G. (2000) Worsening of Parkinson’s disease by citalopram. Parkinsonism Rel. Disord. 6, 111–113.
Gerber, P.E. and Lynd, L.D. (1998) Selective serotonin-reuptake inhibitor-induced movement disorders. Ann. Pharmacother. 32, 692–698.
Gobert, A., Rivet, J.-M., Lejeune, F., et al. (2000) Serotonin 2c receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36, 205–221.
Montastruc, J.L., Fabre, N., and Blin, O. (1995) Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov. Disord. 10, 355–356.
Caley, C.F. and Friedman, J.H. (1992) Does fluoxetine exacerbate Parkinson’s disease? J. Clin. Psychiatry 53, 278–282.
Richard, I.H., Maughn, A., and Kurlan, R. (1999) Do serotonin reuptake inhibitor worsen Parkinson’s disease? A retrospective case series. Mov. Disord. 14, 155–157.
Tesei, S., Antonini, A., Canesi, M., Zecchinalli, A., Mariani, C.B., and Pezzoli, G. (2000) Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov. Disord. 15, 986–989.
Toyama, S.C. and Iakono, R.P. (1994) Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann. Pharmacother. 28, 405–406.
Waters, C.H. (1994) Fluoxetine and selegiline. Can. J. Neurol. Sci. 21, 259–261.
Richard, I., Kurlan, R., Tanner, C., Factor, S., Hubble, J., Suchowersky, 0., and Waters, C. (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease: Parkinson Study Group. Neurology 48, 1070–1077.
Keller, M.B. and Hanks, D.L. (1995) Anxiety symptom relief in depression treatment outcomes. J. Clin. Psychiatry 56(Suppl. 6), 22–29.
Hoffman, W.F. (1985) Treatment of major depression and Parkinson’s disease with combined phenelzine and amantadine [letter]. Am. J. Psychiatry 142, 273.
Hargrave, R. and Ashford, J.W. (1992) Phenelzine treatment of depression in Parkinson’s disease. Am. J. Psychiatry 149, 1751–1752.
Brown, A.S. and Gershon, S. (1993) Dopamine and depression. J. Neural. Transm. 91, 75–109.
Fahn, S. and Chouinard, S. (1998) Experience with tranylcypromine in early Parkinson’s disease. J. Neural. Transm. 52(Suppl.), 49–61.
Sunderland, T., Cohen, R.M., Molchan, S., et al. (1994) High-dose selegiline in treatment-resistant older depressive patients. Arch. Gen. Psychiatry 51, 607–615.
Mann, J.J., Aarons, S.F., Wilner, P.J., et al. (1989) A controlled study of the antidepressant efficacy and side-effects of (-)-deprenyl: a selective monoamino oxidase inhibitor. Arch. Gen. Psychiatry 46, 45–50.
Kuhn, W. and Muller, T. (1996) The clinical potential of deprenyl in neurologic and psychiatric disorders. J. Neural. Transm. 48, 85–93.
Allain, H., Pollak, P., and Neukirch, H.C. (1993) Symptomatic effect of selegiline in de novo parkinsonian patients: the French Selegiline Multicenter Trial. Mov. Disord. 8(Suppl. 1), S36–540.
Parkinson Study Group. (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321, 1364–1371.
Ritter, J.L. and Alexander, B. (1997) Retropsective study of selegiline-antidepressant drug interactions and a review of the literature. Ann. Clin. Psychiatry 9, 7–13.
Angst, J. and Stabl, M. (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106(Suppl.), S109–S113.
Bakish, D., Saxena, B.M., Bowen, R., and D. Souza, J. (1993) Reversible monoamine oxidase A inhibitors in panic disorders. Clin. Neuropharmacol. 16(Suppl. 2), 77–82.
Takats, A., Tarczy, N., Simo, M., Szombathely, E., Bodrogi, A., and Karpati, R. (1994) Moclobemide treatment in Parkinson’s disease with depression. New Trends Clin. Neuropharmacol. 8, 260.
Jansen-Steur, E.N.H. and Ballering, L.A.P. (1997) Moclobemide and selegiline in the treatment of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63, 547–548.
Sieradzan, K., Channon, S., Ramponi, C., Stern, G.M., Lees, A.J., and Youdim, M.B.H. (1995) The therapeutic potential of moclobemide, a selective monoamine oxidase A inhibitor in Parkinson’s disease. J. Clin. Psychopharmacol. 15(Suppl. 2), 51–59.
Sternić, N., Kacar, A., Filipović, S., Svetel, M., and Kostić, V.S. (1998) The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson’s disease. Clin. Neuropharmacol. 21, 93–96.
Silver, J.M. and Yudofski, S.C. (1992) Drug treatment of depression in Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects (Huber, S.J. and Cummings, J.L., eds.), Oxford University Press, New York, pp. 240–254.
Goetz, C.G., Tanner, C.M., and Klawans, H.L. (1984) Bupropion in Parkinson’s disease. Neurology 34, 1092–1094.
Kanner, A.M. (2000) The treatment of depression in various neurological disorders. Syllabi of AAN 4TP.003, 18–30.
Leentjens, A.F., Verhey, F.R., and Vreeling, F.W. (2000) Successful treatment of depression in a Parkinson disease patient with bupropion. Ned. Tijdschr. Geneeskd. 144, 2157–2159.
Kent, J.M. (2000) SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355, 911–918.
Gorman, J.M. (1999) Mirtazapine: clinical overview. J. Clin. Psychiatry 60(Suppl. 17), 9–13.
Fawcett, J. and Barkin, R.L. (1998) Review of the results from the clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J. Affect. Disord. 51, 267–285.
Pact, V. and Giduz, T. (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53, 1154.
Douyon, R., Serby, M., Klutchko, B., and Rotrosen, J. (1989) ECT and Parkinson’s disease revisited: a naturalistic study. Am. J. Psychiatry 146, 1452–1455.
Faber, R. and Trimble, M. (1991) Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov. Disord. 6, 293–303.
Moellentine, C., Rummans, T., Ahlskog, J.E., et al. (1998) Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10, 187–193.
Wengel, S.P., Burke, W.J., Pfeiffer, R.F., Roccaforte, W.H., and Paige, S.R. (1998) Maintenance electroconvulsive therapy for intractable Parkinson’s disease. Am. J. Geriatr. Psychiatry 6, 263–269.
George, M.S., Wassermann, E.M., Kimbrell, T.A., et al. (1997) Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am. J. Psychiatry 154, 1752–1756.
Klein, E., Kreinin, I., Chistyakov, A., et al. (1999) Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch. Gen. Psychiatry 56, 315–320.
Nobler, M.S., Sackeim, H.A., Prohovnik, I., et al. (1994) Regional cerebral blood flow in mood disorders III: treatment and clinical response. Arch. Gen. Psychiatry 51, 884–897.
Pascual-Leone, A., Catala, M.D., and Pascual, A.P. (1996) Lateralized effect of rapid-rate transcranial magnetic stimulation of prefrontal cortex on mood. Neurology 46, 499–502.
Mally, J. and Stone, T.W. (1999) Therapeutic and “dose-dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson’s disease. J. Neurosci. Res. 57, 935–940.
George, M.S., Lisanby, S.H., and Sackeim, H.A. (1999) Transcranial magnetic stimulation: applications in neuropsychiatry. Arch. Gen. Psychiatry 56, 300–311.
Berger, M. and Riemann, D. (1993) Normal and abnormal REM sleep regulation: REM Sleep in depression-an overview. J. Sleep Res. 2, 211–223.
Demet, E.M., Chicz-Demet, A., Fallon, J.H., and Sokolski, K.N. (1999) Sleep deprivation therapy in depressive illness and Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 753–784.
Green, T.D., Reynolds, C.F., Mulsant, B.H., et al. (1999) Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetinem nortriptyline, or placebo. J. Geriatr. Psychiatry Neurol. 12, 67–71.
Perry, W., Benbow, C., West, L., and Rockwell, E. (1993) Sleep deprivation in an elderly man with Parkinson’s disease [letter. Am. J. Psychiatry 150, 350.
Bertolucci, P.H., Andrade, L.A., Lima, J.G., and Carlini, E.A. (1987) Total sleep deprivation and Parkinson’s disease. Arq. Neuropsiqiatr. 45, 224–230.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kostić, V.S., Stefanova, E., Dragašević, N., Potrebić, S. (2003). Diagnosis and Treatment of Depression in Parkinson’s Disease. In: Bédard, MA., Agid, Y., Chouinard, S., Fahn, S., Korczyn, A.D., Lespérance, P. (eds) Mental and Behavioral Dysfunction in Movement Disorders. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-326-2_27
Download citation
DOI: https://doi.org/10.1007/978-1-59259-326-2_27
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-372-5
Online ISBN: 978-1-59259-326-2
eBook Packages: Springer Book Archive